文献速递肿瘤 PET/CT核素与放射性配体治疗

[99mTc]Tc-PSMA-I&S SPECT/CT延迟显像提高复发性前列腺癌病灶检出率

Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer.
PubMed 文献 · J Nucl Med · 2023-05-25

该研究回顾性分析222例早期生化复发前列腺癌患者,比较注射[99mTc]Tc-PSMA-I&S后早期(≤4 h)与延迟(>15 h)SPECT/CT对PSMA PET/CT预设病灶的检出能力,以PSMA PET/CT为参考标准。延迟组患者水平和病灶水平的阳性率均显著高于早期组,多因素分析显示PSMA PET/CT的SUVmax和[99mTc]Tc-PSMA-I&S摄取时间是SPECT/CT病灶可检出性的独立预测因素。作者认为早期生化复发前列腺癌使用[99mTc]Tc-PSMA-I&S SPECT/CT检测病灶时应优先选择延迟显像(>15 h),但PSMA SPECT/CT的表现明显劣于PSMA PET/CT。

要点

  • 延迟显像(>15 h)患者水平阳性率79%(140/178)高于早期显像(≤4 h)的27%(12/44),P<0.05。
  • 延迟显像病灶水平阳性率60%(195/324)高于早期显像的21%(13/62),P<0.05。
  • 作者认为早期生化复发前列腺癌使用[99mTc]Tc-PSMA-I&S SPECT/CT时应优先选择延迟显像(>15 h)。

核心结论

  • 早期生化复发前列腺癌使用[99mTc]Tc-PSMA-I&S SPECT/CT检测病灶时,作者认为应优先选择注射后>15 h的延迟显像。
  • 作者同时指出,PSMA SPECT/CT的表现明显劣于PSMA PET/CT。

研究设计与样本

  • 回顾性分析222例因[99mTc]Tc-PSMA-I&S SPECT/CT而入选放射性引导手术的早期生化复发前列腺癌患者。
  • 按注射后显像时间分为≤4 h组和>15 h组,共分析386个PSMA PET预设病灶,SPECT/CT采用4点法评分。
  • 以PSMA PET/CT为参考标准,行单因素和多因素分析,纳入前列腺特异性抗原、注射[99mTc]Tc-PSMA-I&S活度、Gleason分级分组、初始TNM分期及按大小分层的PSMA PET/CT阳性淋巴结。

主要发现

  • 患者水平阳性率:延迟组79%(140/178) vs 早期组27%(12/44),P<0.05。
  • 病灶水平阳性率:延迟组60%(195/324) vs 早期组21%(13/62),P<0.05。
  • 按病灶大小分层后,两组阳性率相似。
  • 多因素分析显示,PSMA PET/CT的SUVmax和[99mTc]Tc-PSMA-I&S摄取时间是SPECT/CT病灶可检出性的独立预测因素。

关键数值与推荐

  • 早期显像定义为注射后≤4 h,延迟显像定义为注射后>15 h。
  • SPECT/CT病灶评分采用4点法。
  • 以PSMA PET/CT为参考标准。

临床怎么用

  • 作者认为,早期生化复发前列腺癌使用[99mTc]Tc-PSMA-I&S SPECT/CT检测病灶时应优先选择延迟显像(>15 h)。
  • 作者指出PSMA SPECT/CT的表现明显劣于PSMA PET/CT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to compare the ability to detect histopathologically confirmed lymph node metastases by early and delayed [99mTc]Tc-PSMA-I&S SPECT/CT in early biochemically recurrent prostate cancer. Methods: We retrospectively analyzed 222 patients selected for radioguided surgery using [99mTc]Tc-PSMA-I&S SPECT/CT at different time points after injection (≤4 h and >15 h). In total, 386 prostate-specific membrane antigen (PSMA) PET predetermined lesions were analyzed on SPECT/CT using a 4-point scale, and the results were compared between early and late imaging groups, with uni- and multivariate analyses performed including prostate-specific antigen, injected [99mTc]Tc-PSMA-I&S activity, Gleason grade group, initial TNM stage, and, stratified by size, PSMA PET/CT-positive lymph nodes. PSMA PET/CT findings served as the standard of reference. Results: [99mTc]Tc-PSMA-I&S SPECT/CT had a significantly higher positivity rate for detecting lesions in the late than the early imaging group (79%, n = 140/178, vs. 27%, n = 12/44 [P < 0.05] on a patient basis; 60%, n = 195/324, vs. 21%, n = 13/62 [P < 0.05] on a lesion basis). Similar positivity rates were found when lesions were stratified by size. Multivariate analysis found that SUVmax on PSMA PET/CT and the uptake time of [99mTc]Tc-PSMA-I&S were independent predictors for lesion detectability on SPECT/CT. Conclusion: Late imaging (>15 h after injection) should be preferred when [99mTc]Tc-PSMA-I&S SPECT/CT is used for lesion detection in early biochemical recurrence of prostate cancer. However, the performance of PSMA SPECT/CT is clearly inferior to that of PSMA PET/CT.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Berliner C, Steinhelfer L, Chantadisai M, et al. Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer. J Nucl Med. 2023. PMID: 37230531. doi:10.2967/jnumed.122.265252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。